290 results about "Pyran" patented technology

This disclosure provides redox cyclable molecules for energy storage. These molecules belong to either the 4H-pyran-4-ylidene family or include a six-membered aromatic ring with one nitrogen atom at position 1 (pyridinium family) or two nitrogen atoms at positions 1 and 4 (pyrazinium family) or at positions 1 and 3 (pyrimidinium family). Molecules in these families are used as analytes in redox flow batteries.

The present invention relates to the technical field of organic synthesis, and specifically relates to a method for constructing the chirality of a pyran ring in Orforglipron by means of enzymatic catalysis, the method comprising the following steps: step S1, by using SM1 and SM2 as starting materials, carrying out a reaction under the action of a palladium catalyst and a ligand to obtain INT-1; step S2, under the catalysis of Pd / C, subjecting INT-1 to double bond hydrogenation reduction to obtain INT-2; step S3, in the presence of a solvent, a buffer salt system and enzymatic catalysis, subjecting INT-2 to hydrolysis and resolution to obtain a chirally pure intermediate INT-3; step S4, subjecting INT-3 to a Grignard reaction for cyclization, so as to synthesize a lactone intermediate INT-4; and step S5, subjecting INT-4 to reduction by means of Dibal-H, quenching same, performing extraction with dichloromethane, drying same with anhydrous sodium sulfate, and then performing reduction by means of triethylsilane to obtain a compound of general formula A. In the present invention, the chirality is constructed by means of enzymatic catalysis without the need of SFC resolution for separating isomeric impurities during the construction of the chirality, thereby reducing losses and improving yield, obtaining the target product at high yield and high chiral selectivity, and further saving expenses and reducing costs.

2-diarylmethyl-4-aminotetrahydropyran derivatives are disclosed. The compounds include the following genus:or a pharmaceutically acceptable salt thereof. The compounds activate cellular PP2A, suppress oncogenic kinase signaling and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

The application belongs to the field of compound synthesis, and discloses a kind of compound containing seven-membered lactam and pyrone skeleton and its construction and application, and the chemical structure is shown in the following, wherein R1 is selected from any one of hydrogen, alkyl, halogen;R2 is selected from any one of alkyl, aryl;R3 is selected from any one of hydrogen, phenyl.The seven-membered lactam and pyrone skeleton has good drug activity, and can be used for preparing antitumor drugs.The application also discloses a construction method of the seven-membered lactam and pyrone skeleton.The construction method of the seven-membered lactam and pyrone skeleton has the advantages that raw materials and catalysts are cheap and easy to obtain, operation is simple and convenient, and the universality of substrates is wide.

The invention belongs to the field of medical chemistry, and relates to a benzopyrone compound, a benzopyrone composition and application of the benzopyrone compound and the benzopyrone composition in preparation of a medicine for treating hyperuricemia. The chemical structure is as shown in formula I; in the formula, R1 is fluorine or hydrogen; r2 is fluorine or hydrogen; r3 is hydrogen, nitryl or tertiary butyl; r4 is hydrogen, fluorine or trifluoromethyl; and R1, R2, R3 and R4 are not hydrogen at the same time. The benzopyrone compound provided by the invention has good inhibitory activity on XOD, and can reduce the level of uric acid, thereby being beneficial to treatment of hyperuricemia.

This invention provides a method for screening β-galactosidase inhibitors, belonging to the field of pharmaceutical technology. The first step of this method uses fluorescence sensing technology to rapidly identify natural products with β-Gal inhibitory activity. The principle is based on the fluorescence quenching property of p-nitrophenol (PNP) on sulfur quantum dots (SQDs); β-Gal catalyzes the hydrolysis of p-nitrophenyl-β-D-galactopyranoside (PNPG) to generate the specific product PNP; in the presence of β-Gal, PNPG can be enzymatically catalyzed to generate PNP, quenching the fluorescence of SQDs; when screened for β-Gal inhibitory activity, the fluorescence of SQDs can be restored. The second step uses affinity chromatography to capture components in samples with β-Gal inhibitory activity. This method involves immobilizing β-Gal on a support material, eluting with a solvent to obtain components that can bind to β-Gal, and then using liquid chromatography-mass spectrometry (LC-MS) to identify the components. This method can rapidly and accurately screen β-Gal inhibitors from natural products.

The objective is to provide a diol-containing composition that enables the stable production of polycarbonate diol compositions for obtaining polyurethanes suitable for use in paints, coatings, and adhesives. [Solution] A diol-containing composition comprising a diol compound (4) represented by the following general formula (IV) and a tetrahydropyran compound (3-1) represented by the following general formula (III-1). [Formula 1] JPEG2026054816000039.jpg567 (In the above general formula (IV), n is an integer between 3 and 6.) [chemical 2] JPEG2026054816000040.jpg1572 (In the above general formula (III-1), R1 is a C2-C12 alkyl group or hydrogen atom, which may have substituents or heteroatoms.) A polycarbonate diol composition comprising the aforementioned diol-containing composition and a carbonate-based compound as raw materials.

This invention discloses an ERβ-targeted hydrogen peroxide-responsive near-infrared fluorescent probe, its preparation method, and its applications, belonging to the field of medical technology. The fluorescent probes of this invention are dicyanomethylene-4H-benzodihydropyran compounds P1 and P2 containing borate ester groups, with the following structural formula. These fluorescent probes use DCM-OH as a backbone, acting as both a fluorophore and an ERβ ligand. The borate ester group is the H2O2 responsive group. The introduction of the borate ester group disrupts the push-pull effect of the DCM-OH fluorophore, preventing fluorescence emission. However, in a high-concentration H2O2 environment, the borate ester group is specifically cleaved by H2O2, subsequently exhibiting strong initiation fluorescence and enabling tumor imaging in vitro and in vivo. This invention brings new opportunities for the diagnosis and research of prostate cancer.

The invention provides a high-strength and high-toughness photocuring outer coating for a thin-diameter polarization-maintaining optical fiber. The coating comprises the following components: 60-80% of a modified acrylate oligomer; 20-40% of an acrylate monomer; 0.5 to 6% of a photoinitiator; 0.05-1% of an antioxidant; the modified acrylate oligomer is formed by polymerizing oligosaccharide, alkyl acid, (methyl) acrylic acid, an acid catalyst and a polymerization inhibitor, the main chain of the oligosaccharide has a continuous pyranoid ring structure and the polymerization degree is 2-10, and carboxyl in the alkyl acid and hydroxyl on a pyranoid ring are subjected to esterification reaction so as to be grafted on the oligosaccharide to form an alkyl side chain. The high-strength and high-toughness photocuring outer coating for the small-diameter polarization maintaining optical fiber has the advantages of high strength and high flexibility, the curing speed is high by adopting a photocuring mode, and the raw materials are cheap and easy to obtain.

The invention provides a crystal form VI of an acrylamide compound, and the acrylamide compound is (S)-N-(5-((6-(2-(7, 7-dimethyl-1-oxo-1, 3, 4, 6, 7, 8-hexahydro-2H-cyclopentane [4, 5] pyrrolo [1, 2-a] pyrazine-2-yl)-3-(hydroxymethyl) pyridine-4-yl)-4-methyl-3-oxo-3, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-3-(hydroxymethyl) pyridine-4-yl)-4-methyl-3-oxo-3, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-3-(2, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-4- The crystal form VI is a 2-(2, 4-dihydropyrazine-2-yl) amino)-2-(2-methyl-4-(tetrahydro-2H-pyran-4-yl) piperazine-1-yl) 5phenyl) acrylamide compound, and an X-ray powder diffraction pattern of the crystal form VI comprises diffraction peaks with the following 2 theta angle values: 8-3 + / -0.2 degrees, 13.2 + / -0.2 degrees and 18.9 + / -0.2 degrees. The crystal form VI has the advantages of good stability and low hygroscopicity, and is suitable for industrial production of bulk drugs and development of preparation prescriptions.

The present invention relates to a herbicidal composition comprising as active ingredients a mixture of components (A) and (B), wherein component (A) is a compound of formula (I): [Case 1] JPEG2026502851000020.jpg38161, and component (B) is bicyclopyrone or an agrochemically acceptable ester or salt thereof.

The invention provides a synthesis method of a quaternary cycloalkane modified O-glucoside compound shown in formula 3, in the presence of a catalyst, a sugar compound shown in formula 1 with exposed hydroxyl and a quaternary tension ring substrate compound shown in formula 2 are subjected to nucleophilic addition reaction in an organic solvent to prepare the quaternary cycloalkane modified O-glucoside compound shown in formula 3: X is H, CF3 or Cl; a is a dioxolane type compound or a pyran type compound; the catalyst is phosphazene base P4-t-Bu, and the specific structural formula is shown in the specification.

Provided herein are compounds of Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), (II-b2), (II-3), (II-a3), (II-4), (II-a4), (II-5), (II-a5), (II-6), (II-a6), (II-7), (II-a7), (II-7), or (II-a8)), Formula (III) (e.g., Formula (III-1), (III-2), (III-3), (III-4), (III-5), (III-6), (III-7), or (III-8)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), (IV-b2), (IV-a3), (IV-b3), (IV-a4), (IV-b4), (IV-a5), (IV-b5), (IV-a6), (IV-b6), (IV-a7), (IV-b7), (IV-a8), or (IV-b8)), Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), (V-b2), (V-a3), or (V-b3)), Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or Formula (A) (e.g., Formula (I-a1)), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein (e.g., a dysregulated KRas protein (e.g., a mutated or amplified KRas protein)). This disclosure also provides compositions containing the compounds as provided herein, or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.

Novel and useful compounds, such as 2,4-dihydropyrazolo[3',4':4,5]pyrano[2,3-b]pyridines, are disclosed herein. Such compounds may be employed in various treatments, alleviation, or prevention of a group of disorders, such as disorders associated with Tau (tubulin associated unit) protein aggregates, such as neurofibrillary tangles (NFTs), such as Alzheimer's disease (AD).

The invention discloses a preparation method of a cresol trozole trisiloxane intermediate, and belongs to the technical field of fine chemical engineering. The preparation method comprises the following steps: by taking 2, 6-dibromo-4-methylphenol as a raw material, reacting with 3, 4-dihydropyran under the action of p-toluenesulfonic acid, so as to generate an intermediate 2-(2, 6-dibromo-4-methylphenoxy) pyran; reacting with sodium methoxide under the action of a catalyst to generate an intermediate 2-(2-bromo-4-methyl-6-methoxyphenoxy) pyran; then generating a Grignard reagent, carrying out coupling reaction on the Grignard reagent and 3-bromine-2-methallyl, finally reacting with benzotriazole lithium salt, and carrying out acidolysis deprotection to obtain the cresol trozole trisiloxane intermediate. The raw materials are available in the market, the overall yield is high, and a route reference is provided for synthesis of the compounds.

This invention discloses a green synthesis process for 2-chloropyranose-1-yl)-4'-ethoxydiphenylmethane, belonging to the field of pharmaceutical intermediate preparation. The method involves forming a mixture of a substrate in the protected state of Formula I and a reducing agent containing siloxane bonds, which is continuously fed into a microreactor loaded with a confined-domain MOF (Metal-Oxide-Fractions) supported catalyst for room-temperature reduction. The MOF catalyst has a rigid pore size of 1.2~2.5 nm and internally coordinates and anchors metal trifluoromethanesulfonate. This invention utilizes the limiting confinement effect of rigid channels to lock the substrate conformation, blocking the surface attack of reactants and achieving extremely high configuration selectivity. Simultaneously, the efficient mass transfer of the continuous flow microchannel and the online infrared spectroscopy closed-loop control system completely eliminate the need for traditional cryogenic conditions, remove highly corrosive fluorine-containing waste liquid, significantly reduce synthesis costs, and achieve efficient, green, and stable continuous industrial production of this core intermediate.

The invention provides a synthesis method and application of a tetra-substituted pyran compound. The tetra-substituted pyran compound is directly constructed through a one-pot cascade reaction under an organic base catalysis system by taking triketone olefin and allyl ammonium salt as key reaction raw materials. The method has the advantages that the operation is simple and convenient, no water or oxygen is needed, the reaction is efficient, the steps are simple, the method is environment-friendly, the reaction is easy to amplify, and the method has practical value. Activity tests prove that the compounds have certain inhibitory activity on alpha-glucosidase, or can be used for treating diabetes mellitus.

The present application belongs to the technical field of electronic atomization, and particularly relates to a tobacco extract composition, a preparation method and application thereof. The tobacco extract composition comprises methylcyclopentenolone, guaiacol, neophytadiene, cedrene diol, dihydroactinidiolide, maltol, furaneol, palmitic acid, 6-ethyl-5,6-dihydro-2H-pyran-2-one and scopoletin; the range of (methylcyclopentenolone+guaiacol) / neophytadiene is 0.01-2.5 by mass; the guaiacol content is 0.003-0.02 mg / g by dry matter mass; the tobacco roasting aroma is richer, the tobacco roasting sweet note is more obvious, and the tobacco-like feeling is better. The preparation method comprises: extracting tobacco raw materials twice at medium and low temperatures to obtain tobacco flavor substances, extracting the tobacco raw materials at high temperature to obtain smoke flavor substances, and mixing the tobacco flavor substances and the smoke flavor substances at a certain ratio to obtain the tobacco extract composition.

The disclosure relates to a benzopyrylium dye of the formula (I),in which R200, R201, R202, R203, R204, R205, R206, R207 and R208 independently of one another are each hydrogen, C1 to C16 alkyl, C4 to C7 cycloalkyl, C7 to C16 aralkyl, C6 to C10 (het)aryl, hydroxyl, C1 to C6 alkoxy, or dialkylamino, the dialkylamino being selected from the group consisting of diethylamino, dimethylamino, diisopropylamino, a six-membered saturated ring attached via the N of the amino group, which may additionally contain an N or O and may be substituted by nonionic arbitrary radicals, or a combination of at least two thereof, and / or R200 with R201 or R201 with R202 or R202 with R203 and / or R205 with R206 and / or R206 with R207 each independently of one another form a —CH═CH—CH═CH— bridge, and A is a —CH2— or a —CH2—CH2— bridge, where the anion Ann− has a molecular weight of ≥200 g / mol and does not contain a halogen atom.

The invention provides an anti-aging composition and a skin care product. The anti-aging composition is prepared from components in percentage by mass as follows: 5%-40% of hydroxypropyl tetrahydropyrantriol, 5%-40% of a skin feeling / rheology regulator and 2%-12% of a ternary compound, the ternary complex is prepared from the following raw materials: organic acid, amino acid and saccharides. The anti-aging composition provided by the embodiment of the invention can be used for improving the skin penetration of the hydroxypropyl tetrahydropyrantriol.

Disclosed in the present invention are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. Specifically, disclosed in the present invention are a thioether-substituted galactopyranoside derivative, a preparation method therefor, and a use thereof.

The invention discloses a piperazine bridged ring substituted pyrimidinopyran compound and application thereof, and particularly discloses a compound as shown in formula (I ''), (I ') or formula (I), and a stereoisomer and pharmaceutically acceptable salt thereof.

The application relates to a catalyst for preparing 3,4-dihydro-2H-pyran, a preparation method of the catalyst and a method for preparing 3,4-dihydro-2H-pyran by using the catalyst. The catalyst comprises a carrier, an active component and a promoter component, and is prepared by immersing the carrier in an active component precursor aqueous solution, stirring and uniformly standing, and then drying; calcining in an air atmosphere; reducing in a hydrogen atmosphere; immersing in a promoter component precursor aqueous solution, stirring and uniformly standing, and then drying; calcining in an air atmosphere; and reducing in a hydrogen atmosphere. The catalyst according to the application is applied to a process for preparing 3,4-dihydro-2H-pyran by taking tetrahydrofurfuryl alcohol as a raw material, the generation of a tetrahydropyran byproduct is reduced, the selectivity of 3,4-dihydro-2H-pyran is improved, and the difficulty of separation is reduced. The method for preparing 3,4-dihydro-2H-pyran provided by the application has the advantages of easy raw material, a more green route, simple process, high efficiency and continuous production.

The invention provides a method for catalytically synthesizing 7-amino-3-oxabicyclo [3.3. 1] nonyl-6-ene-1-ol by using rare earth, which comprises the following steps of: adding a catalyst and a catalyst, according to the preparation method, rare earth trifluoromethanesulfonate is taken as a catalyst, 6-alkoxy-2, 6-dihydropyran-3-ketone and enamine compounds are taken as raw materials, and the 7-amino-3-oxabicyclo [3.3. 1] nonyl-6-ene-1-ol is prepared by catalyzing (3 + 3) cyclization reaction. The synthesis method provided by the invention is simple in reaction raw material synthesis, low in rare earth salt price, easy in experimental operation and suitable for large-scale preparation. The obtained compound can be applied to the fields of organic synthesis, drug synthesis, organic materials and the like.

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The invention discloses a photochromic spiropyrane derivative containing an adamantyl group and a preparation method and application thereof, the photochromic spiropyrane derivative containing the adamantyl group takes 4-dimethylaminopyridine and dicyclohexylcarbodiimide as catalysts, and 2-(3 ', 3'-dimethyl-6-nitro spiro [chromene-2, 2 '-diketone)-1, 2, 4-triazole-2-yl]-1, 3, 4-triazole-2-yl]-1, 3, 4-triazole-2-yl]-1, 3, 4-triazole-2-yl]-1, 3, 4 According to the invention, 2, 2 '-indoline]-1'-yl) ethanol and an adamantane carboxylic acid compound are subjected to an esterification reaction, adamantanoate series large steric hindrance groups are introduced to spiropyrane molecules, a relatively loose accumulation mode of the compound is caused, and pi-pi accumulation of the spiropyrane molecules is effectively prevented, so that a photochromic reaction of spiropyrane in a solid state is realized; the preparation method is simple, post-treatment is convenient, and the prepared photochromic spiropyrane derivative containing the adamantyl group is high in yield and good in fat solubility.

The application provides a preparation method of high-optical-purity piperlongumin, characterized by the following steps: 2H-pyrane-2,4(3H)-dione and styrene are used to generate a corresponding chiral intermediate under the catalysis of a transition metal and a chiral phosphoric acid ligand, and then the chiral intermediate is subjected to etherification to obtain high-optical-purity piperlongumin; the process is simple, efficient, high in yield, green and environment-friendly, and is suitable for large-scale industrial production.

The application belongs to the technical field of polymers, and particularly relates to a polyurethane material and a preparation method and application thereof. The polyurethane material comprises the following components in parts by weight: polycaprolactone diol 10-50 parts, hexamethylene diisocyanate 1-10 parts, catalyst 0.05-0.3 parts, spiro-pyran diol 0.5-5 parts, and crosslinking agent 1-6 parts. The molecular formula of the spiro-pyran diol is shown in the description. The polyurethane material prepared by the application can realize two response functions under a single stimulus, and significantly expands the development potential and application field of the double-way shape memory material.